[HTML][HTML] Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia

L Dupuis-Maguiraga, M Noret, S Brun… - PLoS neglected …, 2012 - journals.plos.org
At the end of 2005, an outbreak of fever associated with joint pain occurred in La Réunion.
The causal agent, chikungunya virus (CHIKV), has been known for 50 years and could thus …

[HTML][HTML] Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

…, E D'ortenzio, O Puéchal, C Semaille, M Noret… - Clinical Microbiology …, 2021 - Elsevier
Objectives Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19
diagnostics. The high technicalities of nasopharyngeal sampling and molecular assays, as …

[HTML][HTML] An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients …

…, JC Richard, J Reuter, T Staub, B Lina, M Noret… - Clinical Microbiology …, 2021 - Elsevier
Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir,
lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to …

Interleukin 6, RANKL, and osteoprotegerin expression by chikungunya virus–infected human osteoblasts

M Noret, L Herrero, N Rulli, M Rolph… - The Journal of …, 2012 - academic.oup.com
TO THE EDITOR—Chow et al [1] recently implicated interleukin 6 (IL-6) in the persistent
arthralgia that occurs in some patients following infection with chikungunya virus (CHIKV). They …

Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France

M Noret, S Balavoine, C Pintado, M Siguier, A Brun… - Aids, 2018 - journals.lww.com
Background: On-demand oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) has
been approved for pre-exposure prophylaxis (PrEP) in MSM in France following the results …

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised …

…, P Tattevin, A Rommerskirchen, M Noret… - The Lancet Infectious …, 2024 - thelancet.com
Background Staphylococcus aureus bloodstream infection is treated with at least 14 days of
intravenous antimicrobials. We assessed the efficacy and safety of an early switch to oral …

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

…, M Murris-Espin, JC Navellou, M Noret… - The Lancet Infectious …, 2022 - thelancet.com
We reported the preliminary results of the DisCoVeRy trial regarding the efficacy and safety
of remdesivir in hospitalised patients with COVID-19 in February, 2022. 1 Remdesivir did not …

Early oral switch in low-risk Staphylococcus aureus bloodstream infection

…, V Vitrat, P Tattevin, A Rommerskirchen, M Noret… - medRxiv, 2023 - medrxiv.org
Background: Staphylococcus aureus bloodstream infection (SAB) is treated with at least 14
days of intravenously administered antimicrobials. We assessed the efficacy and safety of an …

[HTML][HTML] Effect of professional and extra-professional exposure on seroprevalence of SARS-CoV-2 infection among healthcare workers of the French Alps: a …

…, B Chanzy, S Nguyen, A Valran, A Bosch, M Noret… - Vaccines, 2021 - mdpi.com
We aimed to report SARS-CoV-2 seroprevalence after the first wave of the pandemic among
healthcare workers, and to explore factors associated with an increased infection rate. We …

A randomized controlled trial to study the transmission of SARS-CoV-2 and other respiratory viruses during indoor clubbing events (ANRS0066s ITOC study)

…, J Goupil de Bouillé, L Menant, M Noret… - Clinical Infectious …, 2023 - academic.oup.com
Background In the context of the circulation of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta) variant, vaccination re-authorized mass indoor …